Freenome to Participate in the Piper Sandler 38th Annual Healthcare Conference
News originally published by
GlobeNewswireBRISBANE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (NASDAQ: FRNM), a personalized cancer detection company using an AI-driven multiomics platform to develop and optimize single- and multi-cancer blood tests, today announced company management will participate in the Piper Sandler 38th Annual Healthcare Conference.
Management will participate in a fireside chat from 4:30pm to 4:55pm Eastern Time on Tuesday, Dec. 1, 2026.
A live and archived webcast of the events will be available on the “Events” section of the Freenome investor relations website at https://investors.freenome.com/news-events/events.
About Freenome
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company’s proprietary AI-driven multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome’s development of FDA-approved SimpleScreen CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional single- and multi-cancer indications is designed to increase cancer screening participation among millions of at-risk individuals.
Freenome Contacts:
Investor Relations
Gilmartin Group LLC
investor-relations@freenome.com
Media Contact
Ryan Flinn
The Grace Group
ryan@gracegroup.us
media@gracegroup.us
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.